Beijing Mayor Visited Sinovac on Promoting Development of Biopharmaceutical Industry

2009-04-27

In the morning of April 22^nd, 2009, Beijing government officers , Qi Liu, Jinlong Guo, Anshun Wang, Shixiang Li, Fengtong Zhao, Zhongwen Gou, Xiangyang Ding and other officers from relative governmental departments, total more than 40 governors, came to Sinovac to perform the specific research related to “Improve the capability of independent innovation and promote the development of biopharmaceutical industry” on pharmaceutical industry and academic organizations. They were accompanied by the head of Administrative Committee of Zhongguancun Science Park, Wei Dai, the head of Haidian Chinese Communist Party Committee, Weike Tan, the head of Haidian District Government, Fusheng Lin, etc.

In the filling & packaging plant of Sinovac, officers inspected two modern packaging lines and learned the manufacturing process. Sinovac CEO, Weidong Yin reported Sinovac’s R&D and industrialization projects to these officers, and introduced the situation of current operation and future development plan as well as the focus of investment under the economic crisis. Weidong Yin said, “Developing towards an enterprise group is our goal. We have to contribute our efforts to the aim of Beijing development.

After reporting, Qi Liu and other government officers discussed with Weidong Yin about building up Zhongguancun National Innovation Park, the tax policy about companies’ re-investment and the development of biopharmaceutical industry.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, and poliomyelitis.

SINOVAC's COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The Healive®, a hepatitis A vaccine manufactured by the Company, passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine, that was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) was prequalified by WHO.

SINOVAC was the first company that granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

SINOVAC has been continually dedicating itself to new vaccine research and development, with more combination vaccine products in the pipeline, and constantly exploring opportunities in the international market. SINOVAC looks forward to conducting more extensive and in-depth trade and cooperation with more countries, enterprises, and professional institutions.

For more information, please see the Company’s website at www.sinovac.com.

Contacts

Sinovac Biotech Ltd.

Helen Yang

+86-10-8279-9871 or

+86-10-5693-1897

Fax: +86-10-6296-6910

ir@sinovac.com

ICR Inc.

Bill Zima

U.S.: 1-646-308-1707

william.zima@icrinc.com